Promising ASX Penny Stocks To Consider In September 2026

The Australian share market is currently facing headwinds, with the ASX 200 experiencing its steepest decline since March due to rising oil prices, increasing bond yields, and potential interest rate hikes. Amid these challenges, investors are seeking opportunities that balance affordability with growth potential. Penny stocks, often representing smaller or newer companies, offer such prospects; when backed by strong financials and fundamentals, they can present valuable opportunities for growth even in uncertain times.

Let's dive into some prime choices out of the screener.

Macmahon Holdings (ASX:MAH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Macmahon Holdings Limited provides surface and underground mining, mining support, and civil infrastructure services to mining companies in Australia and Southeast Asia, with a market cap of A$2.08 billion.

Operations: The company's revenue is derived from two main segments: Mining, which contributes A$1.93 billion, and Civil, which generates A$672.43 million.

Market Cap: A$2.08B

Macmahon Holdings Limited, with a market cap of A$2.08 billion, is trading at 34.5% below its estimated fair value, making it an attractive option in the penny stock space. The company has demonstrated consistent earnings growth over the past five years at 15.5% annually and reported a net income increase to A$101.14 million for the year ending June 2026 from A$73.94 million previously. Despite a rise in debt-to-equity ratio over five years to 44%, its debt is well-covered by operating cash flow (92.3%). Recent board changes and dividend increases indicate active corporate governance and shareholder returns focus.

• Take a closer look at Macmahon Holdings' potential here in our financial health report.
• Gain insights into Macmahon Holdings' future direction by reviewing our growth report.

Mont Royal Resources (ASX:MRZ)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Mont Royal Resources Limited is involved in the development and exploration of mineral properties in Canada, with a market capitalization of A$18.67 million.

Operations: The company's revenue is derived entirely from its Mineral Exploration and Development segment, amounting to A$0.03 million.

Market Cap: A$18.67M

Mont Royal Resources, with a market cap of A$18.67 million, remains in the pre-revenue phase, focusing on mineral exploration and development in Canada. The company recently entered a Joint Study Agreement with Alta Resource Technologies to explore rare earth separation technologies for its Ashram Project, potentially advancing into high-purity oxide production. Despite having no debt and short-term assets exceeding liabilities (A$8M vs. A$374.9K), Mont Royal faces challenges with an inexperienced management team and less than a year of cash runway based on current free cash flow trends, indicating potential financial constraints ahead.

• Navigate through the intricacies of Mont Royal Resources with our comprehensive balance sheet health report here.
• Examine Mont Royal Resources' past performance report to understand how it has performed in prior years.

Medical Developments International (ASX:MVP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Medical Developments International Limited offers emergency medical solutions across Australia, Europe, the United States, and other international markets with a market cap of A$56.33 million.

Operations: The company generates revenue from two main segments: Respiratory, contributing A$10.95 million, and Pain Management, accounting for A$31.62 million.

Market Cap: A$56.33M

Medical Developments International, with a market cap of A$56.33 million, shows promising growth potential in the penny stock segment. The company reported sales of A$42.57 million for the year ending June 2026, up from A$39.06 million previously, and net income increased significantly to A$0.626 million from A$0.094 million last year. Earnings grew by a very large margin over the past year at 566%, outpacing industry averages and highlighting robust financial progress despite low return on equity at 1.1%. The firm is debt-free with strong asset coverage over liabilities and has experienced management and board teams in place.

• Get an in-depth perspective on Medical Developments International's performance by reading our balance sheet health report here.
• Understand Medical Developments International's earnings outlook by examining our growth report.

Summing It All Up

• Get an in-depth perspective on all 395 ASX Penny Stocks by using our screener here.
• Ready For A Different Approach? Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com